Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its earnings data after the market closes on Thursday, November 14th. Analysts expect Aurinia Pharmaceuticals to post earnings of ($0.19) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
AUPH stock opened at $5.01 on Wednesday. The company has a fifty day moving average price of $4.99 and a two-hundred day moving average price of $5.91. Aurinia Pharmaceuticals has a one year low of $3.52 and a one year high of $7.85. The stock has a market cap of $484.63 million, a price-to-earnings ratio of -6.59 and a beta of 1.07.
A number of research firms have commented on AUPH. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, October 17th. ValuEngine cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 10th. Royal Bank of Canada reaffirmed a “buy” rating and set a $11.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 8th. Citigroup began coverage on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. They set an “outperform” rating and a $14.00 price objective for the company. Finally, Oppenheimer began coverage on shares of Aurinia Pharmaceuticals in a research report on Tuesday, September 10th. They set an “outperform” rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $15.18.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Story: NASDAQ
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.